120.40
price down icon2.28%   -2.81
 
loading
Precedente Chiudi:
$123.21
Aprire:
$122.86
Volume 24 ore:
6.83M
Relative Volume:
0.95
Capitalizzazione di mercato:
$149.38B
Reddito:
$29.05B
Utile/perdita netta:
$8.11B
Rapporto P/E:
18.65
EPS:
6.4563
Flusso di cassa netto:
$9.16B
1 W Prestazione:
-0.68%
1M Prestazione:
-2.43%
6M Prestazione:
+7.45%
1 anno Prestazione:
+30.33%
Intervallo 1D:
Value
$119.53
$123.62
Intervallo di 1 settimana:
Value
$118.78
$123.74
Portata 52W:
Value
$88.57
$128.70

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Nome
Gilead Sciences Inc
Name
Telefono
(650) 574-3000
Name
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Name
Dipendente
17,600
Name
Cinguettio
@GileadSciences
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
GILD's Discussions on Twitter

Confronta GILD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
120.40 152.86B 29.05B 8.11B 9.16B 6.4563
Drug Manufacturers - General icon
LLY
Lilly Eli Co
1,027.51 903.41B 59.42B 18.41B 6.44B 20.22
Drug Manufacturers - General icon
JNJ
Johnson Johnson
211.58 505.98B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
223.32 395.86B 59.64B 2.36B 19.68B 1.3253
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
132.57 253.97B 54.45B 14.42B 17.15B 7.333
Drug Manufacturers - General icon
MRK
Merck Co Inc
100.30 245.75B 63.90B 19.05B 13.05B 7.5596

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-11-24 Ripresa Truist Buy
2025-11-13 Iniziato Scotiabank Sector Outperform
2025-08-19 Aggiornamento Daiwa Securities Neutral → Outperform
2025-08-08 Aggiornamento Truist Hold → Buy
2025-07-25 Aggiornamento Needham Hold → Buy
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-03-04 Reiterato Oppenheimer Outperform
2025-02-18 Aggiornamento Deutsche Bank Hold → Buy
2025-02-13 Aggiornamento DZ Bank Hold → Buy
2025-01-10 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2024-12-10 Ripresa BofA Securities Buy
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Buy
2024-11-08 Downgrade Maxim Group Buy → Hold
2024-10-21 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-17 Iniziato Bernstein Outperform
2024-10-07 Aggiornamento Wells Fargo Equal Weight → Overweight
2024-07-08 Aggiornamento Raymond James Mkt Perform → Outperform
2024-05-01 Reiterato Maxim Group Buy
2024-04-24 Aggiornamento HSBC Securities Reduce → Hold
2024-02-22 Downgrade Truist Buy → Hold
2023-11-09 Iniziato Deutsche Bank Hold
2023-09-08 Aggiornamento BofA Securities Neutral → Buy
2023-09-06 Iniziato HSBC Securities Reduce
2023-07-24 Reiterato Barclays Equal Weight
2023-05-16 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-04-28 Ripresa Piper Sandler Overweight
2023-01-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Ripresa BofA Securities Neutral
2022-12-09 Downgrade DZ Bank Buy → Hold
2022-10-31 Aggiornamento Barclays Underweight → Equal Weight
2022-10-28 Reiterato BMO Capital Markets Market Perform
2022-10-28 Reiterato Cowen Outperform
2022-10-28 Reiterato JP Morgan Overweight
2022-10-28 Reiterato Jefferies Buy
2022-10-28 Aggiornamento Piper Sandler Neutral → Overweight
2022-10-28 Reiterato RBC Capital Mkts Outperform
2022-10-28 Aggiornamento Truist Hold → Buy
2022-10-28 Reiterato Wells Fargo Equal Weight
2022-10-04 Aggiornamento JP Morgan Neutral → Overweight
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-05-23 Iniziato SVB Leerink Mkt Perform
2022-02-28 Downgrade BMO Capital Markets Outperform → Market Perform
2022-02-02 Reiterato BMO Capital Markets Outperform
2022-02-02 Reiterato BofA Securities Neutral
2022-02-02 Reiterato RBC Capital Mkts Outperform
2022-02-02 Reiterato Truist Hold
2022-02-02 Reiterato Wells Fargo Equal Weight
2022-01-28 Aggiornamento Argus Hold → Buy
2022-01-06 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-12-06 Iniziato Goldman Neutral
2021-11-19 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-11-19 Ripresa Piper Sandler Neutral
2021-10-20 Ripresa Cowen Outperform
2021-07-30 Reiterato BMO Capital Markets Market Perform
2021-07-30 Reiterato RBC Capital Mkts Outperform
2021-04-01 Aggiornamento Bernstein Mkt Perform → Outperform
2021-03-30 Aggiornamento Redburn Neutral → Buy
2021-01-19 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-01-04 Aggiornamento Guggenheim Neutral → Buy
2020-11-03 Ripresa Morgan Stanley Equal-Weight
2020-10-28 Iniziato UBS Neutral
2020-09-30 Ripresa Jefferies Buy
2020-09-15 Aggiornamento Maxim Group Hold → Buy
2020-07-31 Reiterato Credit Suisse Neutral
2020-07-31 Reiterato Morgan Stanley Equal-Weight
2020-07-31 Reiterato Piper Sandler Overweight
2020-07-31 Reiterato RBC Capital Mkts Outperform
2020-07-31 Reiterato SunTrust Hold
2020-07-31 Reiterato Wells Fargo Equal Weight
2020-07-20 Aggiornamento Credit Suisse Underperform → Neutral
2020-06-03 Aggiornamento SVB Leerink Mkt Perform → Outperform
2020-05-26 Aggiornamento SunTrust Sell → Hold
2020-05-01 Downgrade JP Morgan Overweight → Neutral
2020-05-01 Downgrade Raymond James Outperform → Mkt Perform
2020-05-01 Downgrade SunTrust Hold → Sell
2020-04-27 Downgrade UBS Buy → Neutral
2020-04-20 Downgrade BMO Capital Markets Outperform → Market Perform
2020-04-20 Downgrade Wells Fargo Overweight → Equal Weight
2020-04-17 Downgrade CFRA Hold → Sell
Mostra tutto

Gilead Sciences Inc Borsa (GILD) Ultime notizie

pulisher
09:31 AM

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $151.00 at Morgan Stanley - MarketBeat

09:31 AM
pulisher
08:43 AM

Treasurer of the State of North Carolina Has $85.51 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat

08:43 AM
pulisher
04:48 AM

BI Asset Management Fondsmaeglerselskab A S Acquires 140,158 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

04:48 AM
pulisher
04:48 AM

Gilead Sciences, Inc. $GILD Shares Sold by Benjamin Edwards Inc. - MarketBeat

04:48 AM
pulisher
04:08 AM

BlueCrest Capital Management Ltd Buys Shares of 13,553 Gilead Sciences, Inc. $GILD - MarketBeat

04:08 AM
pulisher
03:50 AM

AQR Capital Management LLC Has $272.21 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat

03:50 AM
pulisher
03:38 AM

Ameriprise Financial Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

03:38 AM
pulisher
03:32 AM

Gilead, Arcus scrap late-stage trial of cancer drug combo - 1470 & 100.3 WMBD

03:32 AM
pulisher
03:28 AM

Gilead Sciences, Inc. $GILD Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat

03:28 AM
pulisher
Dec 12, 2025

‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure - BioSpace

Dec 12, 2025
pulisher
Dec 12, 2025

GILEAD SCIENCES (GILD): Morgan Stanley Raises Price Target, Main - GuruFocus

Dec 12, 2025
pulisher
Dec 12, 2025

Arcus cancels work on Gilead-partnered cancer combo after trial setback - BioPharma Dive

Dec 12, 2025
pulisher
Dec 12, 2025

Arcus scraps late-stage cancer trial after weak survival data - Reuters

Dec 12, 2025
pulisher
Dec 12, 2025

GILD: Gilead and Arcus End STAR-221 Study Due to Lack of Efficac - GuruFocus

Dec 12, 2025
pulisher
Dec 12, 2025

Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update - marketscreener.com

Dec 12, 2025
pulisher
Dec 12, 2025

Morgan Stanley Adjusts PT on Gilead Sciences to $151 From $147, Maintains Overweight Rating - marketscreener.com

Dec 12, 2025
pulisher
Dec 12, 2025

Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug - Seeking Alpha

Dec 12, 2025
pulisher
Dec 12, 2025

Gilead Sciences, Inc. $GILD Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - MarketBeat

Dec 12, 2025
pulisher
Dec 12, 2025

Sei Investments Co. Raises Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Dec 12, 2025
pulisher
Dec 12, 2025

NewEdge Advisors LLC Has $11.81 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Dec 12, 2025
pulisher
Dec 12, 2025

Alliancebernstein L.P. Sells 809,531 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Dec 12, 2025
pulisher
Dec 11, 2025

Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer - Oncodaily

Dec 11, 2025
pulisher
Dec 11, 2025

Ex-Dividend Reminder: Gilead Sciences, Merck and Horace Mann Educators - Nasdaq

Dec 11, 2025
pulisher
Dec 11, 2025

January 2026 Options Now Available For Gilead Sciences (GILD) - Nasdaq

Dec 11, 2025
pulisher
Dec 11, 2025

The Manufacturers Life Insurance Company Sells 95,568 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Dec 11, 2025
pulisher
Dec 11, 2025

Who Owns Gilead Sciences? Top Shareholders and Recent Insider Trades - TIKR.com

Dec 11, 2025
pulisher
Dec 11, 2025

CIBC Asset Management Inc Sells 28,874 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Dec 11, 2025
pulisher
Dec 10, 2025

Wells Fargo Maintains Gilead Sciences (GILD) Overweight Recommendation - Nasdaq

Dec 10, 2025
pulisher
Dec 10, 2025

GILD: Wells Fargo Raises Price Target for Gilead Sciences | GILD Stock News - GuruFocus

Dec 10, 2025
pulisher
Dec 10, 2025

Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD) - Insider Monkey

Dec 10, 2025
pulisher
Dec 10, 2025

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $133.00 at HSBC - MarketBeat

Dec 10, 2025
pulisher
Dec 10, 2025

Wells Fargo & Company Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat

Dec 10, 2025
pulisher
Dec 10, 2025

Why You Might Be Interested In Gilead Sciences, Inc. (NASDAQ:GILD) For Its Upcoming Dividend - simplywall.st

Dec 10, 2025
pulisher
Dec 10, 2025

Wells Fargo Adjusts Price Target on Gilead Sciences to $150 From $145, Maintains Overweight Rating - marketscreener.com

Dec 10, 2025
pulisher
Dec 10, 2025

HSBC Adjusts Price Target on Gilead Sciences to $133 From $110, Maintains Hold Rating - marketscreener.com

Dec 10, 2025
pulisher
Dec 10, 2025

Here's What We Like About Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend - Yahoo Finance

Dec 10, 2025
pulisher
Dec 10, 2025

30,000 Shares in Gilead Sciences, Inc. $GILD Bought by Diadema Partners LP - MarketBeat

Dec 10, 2025
pulisher
Dec 10, 2025

Dymon Asia Capital Singapore PTE. LTD. Purchases Shares of 18,000 Gilead Sciences, Inc. $GILD - MarketBeat

Dec 10, 2025
pulisher
Dec 10, 2025

Ariel Investments LLC Has $40.90 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat

Dec 10, 2025
pulisher
Dec 09, 2025

Investment Management Corp of Ontario Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Dec 09, 2025
pulisher
Dec 09, 2025

Lombard Odier Asset Management Switzerland SA Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat

Dec 09, 2025
pulisher
Dec 09, 2025

State Street Corp Sells 335,515 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Dec 09, 2025
pulisher
Dec 09, 2025

Ossiam Sells 15,066 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Dec 09, 2025
pulisher
Dec 09, 2025

Jump Financial LLC Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat

Dec 09, 2025
pulisher
Dec 09, 2025

Three Catalysts Driving Investor Attention Toward Gilead Sciences - AD HOC NEWS

Dec 09, 2025
pulisher
Dec 09, 2025

Gilead Sciences, Inc. $GILD Shares Sold by Bank of Nova Scotia - MarketBeat

Dec 09, 2025
pulisher
Dec 08, 2025

ASH25: CAR-T Leaders Gilead, J&J Show in Multiple Myeloma; Fulcrum Rises on Sickle Cell Data - BioSpace

Dec 08, 2025
pulisher
Dec 08, 2025

WINTON GROUP Ltd Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat

Dec 08, 2025
pulisher
Dec 08, 2025

ASH: Gilead preps filing for anito-cel on iMMagine-1 data - Pharmaphorum

Dec 08, 2025
pulisher
Dec 08, 2025

What Does the Market Think About Gilead Sciences Inc? - Benzinga

Dec 08, 2025
pulisher
Dec 08, 2025

Gilead Sciences, Inc. $GILD Shares Bought by Natixis - MarketBeat

Dec 08, 2025

Gilead Sciences Inc Azioni (GILD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Gilead Sciences Inc Azioni (GILD) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Bluestone Jeffrey
Director
Nov 28 '25
Sale
125.08
5,000
625,400
8,920
Kramer Kelly A.
Director
Nov 26 '25
Option Exercise
81.00
2,806
227,286
4,145
Kramer Kelly A.
Director
Nov 28 '25
Option Exercise
81.00
2,805
227,205
4,144
Kramer Kelly A.
Director
Nov 26 '25
Sale
127.11
2,806
356,671
1,339
Kramer Kelly A.
Director
Nov 28 '25
Sale
127.10
2,805
356,516
1,339
O'Day Daniel Patrick
Chairman & CEO
Nov 28 '25
Sale
126.54
10,000
1,265,444
571,203
drug_manufacturers_general PFE
$25.85
price up icon 0.19%
$317.74
price up icon 0.11%
drug_manufacturers_general SNY
$48.68
price down icon 0.37%
drug_manufacturers_general NVO
$50.18
price down icon 0.22%
drug_manufacturers_general MRK
$100.30
price up icon 1.30%
Capitalizzazione:     |  Volume (24 ore):